Cytek Biosciences Inc (CTKB)
Debt-to-equity ratio
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-term debt | US$ in thousands | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | 395,737 | 385,463 | 389,123 | 392,614 | 393,064 | 415,524 | 424,179 | 423,460 | 425,295 | 416,447 | 411,027 | 407,236 | 406,458 | 403,055 | -11,300 | -15,072 | -16,028 |
| Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
December 31, 2024 calculation
Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $—K ÷ $395,737K
= 0.00
The debt-to-equity ratio of Cytek Biosciences Inc has shown a consistent improvement over the past few years. As per the data provided, the ratio was not available from December 2020 to June 2022, indicating a lack of debt during this period.
Starting from September 2021, the debt-to-equity ratio is reported as 0.00, which signifies that the company had no debt and its equity fully financed its operations. This trend continued throughout the years up to December 2024, indicating a debt-free capital structure.
A debt-to-equity ratio of 0.00 typically suggests a conservative financial strategy with minimal reliance on debt financing. This can be viewed positively by investors as it indicates lower financial risk and potentially better financial stability for the company. However, it's important to note that while a low ratio can be advantageous, it may also indicate underutilization of debt to potentially leverage growth opportunities if managed prudently.
Peer comparison
Dec 31, 2024